# 1st Gen Model Abbott Laboratories Pharmaceutical preparations

Subscribe >> Deal exit on
July 24, 2017
Deal entry on
July 24, 2017
3.44%Expected margin
49.23% successful of 65 deals
$50.84 Last close price
at 21-jul-2017

ABT

Model's trade recommendations -4.68% Return for period

-11.03% Annual return

$85.77B Market Cap

β 1.07  

ABT

Model (following trade recommendations)

ABT

Underlying stock

S&P 500

Index
Return for period -4.68%
3.59%
1.78%
52wk return -21.96%
17.77%
16.82%
52wk Range
37.60—50.85
2000.54—2399.63
Sortino ratio -1.30
Sharpe ratio -1.09
Norm. RMSE 0.24%
Downside risk 8.83%
Volatility 10.55%
  • 1.06 (2.14%) Div (Yield)
  • STRONG BUY Analysts consensus recommendation

Abbott is a global healthcare company devoted to improving life through the development of products and technologies that span the breadth of healthcare. They have a portfolio of leading, science-based offerings in diagnostics, medical devices, nutritionals and branded generic pharmaceuticals.

Industry sector: Medical

Sector classification: Pharmaceutical preparations

Deep Learning based analysis and prediction model for Abbott Laboratories (ABT) stock is a 1st Generation Non-linear Autoregresive with exogenous variable(s) (NARX) model based on the Recurrent Neural Network architecture.

Model is in the production pipeline since April 29, 2015.

Market data for ABT model training are being downloaded from the Quandl premium datasets on a daily basis.

Model is being retrained on a daily basis.

Float 1722M
P/E 21.77
Shares Outstanding 1735M
% Held by Insiders 0.76%
% Held by Institutions 71.02%
EPS (last reported FY) $2.20
EPS (last reported Q) $0.48
EPS, estimated (last reported Q) $0.43
Total revenues $21 B
Net income $1 B